Selenium nanoparticles as adjunctive therapy in sepsis: A pilot randomized clinical trial - PubMed
2 months ago
- #Sepsis
- #Clinical Trial
- #Nanomedicine
- Selenium nanoparticles (SeNPs) were tested as adjunctive therapy in sepsis patients with immune dysfunction.
- A pilot randomized clinical trial was conducted with 70 patients, 68 completed the trial (34 per group).
- Patients received either standard care alone or standard care supplemented with SeNPs (400 μg selenium daily).
- Primary endpoint was immune function, assessed by lymphocyte counts and subsets on days 1, 4, 7, and 10.
- SeNPs supplementation improved immune function, with higher total lymphocyte counts and increased CD3+, CD4+, and CD8+ T cell subsets.
- SeNPs also reduced inflammation, indicated by lower levels of pro-inflammatory cytokines IL-6 and HMGB1.
- Protective effects on multiple organ functions were observed, along with decreased markers of systemic infection.
- SeNPs supplementation reduced ICU and hospital mortality with no reported adverse events.
- Findings suggest SeNPs enhance immune function, attenuate inflammation, and protect against organ dysfunctions in sepsis patients.